Submitted by Anonymous (not verified) on 20 September 2023 - 14:33
Human medicines European public assessment report (EPAR): Hefiya, adalimumab, Spondylitis, Ankylosing;Hidradenitis Suppurativa;Psoriasis;Arthritis, Juvenile Rheumatoid;Uveitis, Date of authorisation: 26/07/2018, Revision: 14, Status: Authorised
Source: